PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2024Journal for ImmunoTherapy of Cancer7 citationsOpen Access

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

View Full Paper

Authors

MAMichael B. AtkinsOJOpeyemi A. JegedeNHNaomi B. Haas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Atkins et al. (2024) studied this question.

synapsesocial.com/papers/68e70ef4b6db6435876883afhttps://doi.org/10.1136/jitc-2023-008293
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 2142024 · 23 citations
  2. 2Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma2026 · 3 citations
  3. 3Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).2024 · 1 citations
  4. 4Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.2025
  5. 563P Treatment-free survival (TFS) in patients (pts) with mNSCLC treated with 1L nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in CheckMate (CM) 9LA2024 · 1 citations